- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05072782
Behandling av moderat postoperativt tilbakefall ved Crohns sykdom: en randomisert kontrollert utprøving av terapeutisk eskalering, POMEROL-forsøket. (POMEROL) (POMEROL)
Study type : A 30 months, multicentre, open-label strategic randomized controlled trial
Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).
Treatments :
Stratification at inclusion according to prophylactic therapy.
Patients randomized in 2 arms:
- Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
- Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Number of patients : 360 patients in approximatively 25 sites in France.
Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))
Endpoints:
Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.
Secondary endpoints:
-
Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months
-
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
-
Proportion of patients with an i0 modified Rutgeerts score at 12 months
-
PRO2 score at 12 months
-
Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND
- increased CRP compared to inclusion, at least + 10 mg/l
- OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
-
Surgical recurrence within 12 months: need for a new ileocolonic resection
-
Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy
-
Time to clinical postoperative recurrence
-
Serious adverse events
-
Quality of life: EQ5D-5L questionnaire
-
Work productivity: Work Productivity and Activity Impairment questionnaire
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Paris, Frankrike, 75009
- GETAID
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Crohn's disease diagnosed according usual criteria
- Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
- Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
- Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading
Exclusion Criteria:
- Patients with an ostomy
- Ulcerative colitis or IBD type unclassified
- Ileorectal or ileal pouch-anal anastomosis
- Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
- Patients with obstructive symptoms of CD defined by a CDOS > 4
- Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
- Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
- Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
- Patients in whom not all inflammatory lesions have been removed at index surgery
- Patients with active perianal Crohn's disease
- Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
- Pregnant women
- Patients under legal protection or unable to express their consent.
- Patients not affiliated to a health insurance system.
- Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Status quo arm
If the patient received no prophylactic therapy after resection, no treatments will be started. If the patient received a prophylactic therapy after resection, the same will be continued at the same dose. |
Stratification 1 : No treatments Stratification 2 : Immunosuppressors at same dose |
|
Eksperimentell: Therapy escalation arm
Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards. |
Stratification 1: Infliximab-CT-P13 Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
Tidsramme: Month12
|
Number of patients with an i0-i1 modified Rutgeerts score at 12 months. |
Month12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
Tidsramme: Month 12
|
Number of patients with an i3-i4 modified Rutgeerts score at 12 months |
Month 12
|
|
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
Tidsramme: Month 12
|
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months |
Month 12
|
|
Proportion of patients with an i0 modified Rutgeerts score at 12 months
Tidsramme: Month 12
|
Proportion of patients with an i0 modified Rutgeerts score at 12 months |
Month 12
|
|
Patient Reporting Outcome score at 12 months.
Tidsramme: Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission). |
Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
|
Clinical postoperative recurrence
Tidsramme: Baseline, Month 4, Month 8, Month 12
|
Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND
Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units) |
Baseline, Month 4, Month 8, Month 12
|
|
Surgical recurrence within 12 months
Tidsramme: Baseline, Month 4, Month 8, Month 12
|
Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months |
Baseline, Month 4, Month 8, Month 12
|
|
Endoscopic dilatation within 12 months
Tidsramme: Baseline, Month 4, Month 8, Month 12
|
Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months |
Baseline, Month 4, Month 8, Month 12
|
|
Time to clinical postoperative recurrence will be assessed
Tidsramme: Baseline, Month 4, Month 8, Month 12
|
Time to clinical postoperative recurrence will be assessed |
Baseline, Month 4, Month 8, Month 12
|
|
Serious adverse events
Tidsramme: Screening, Baseline, Month 4, Month 8, Month 12
|
Occurence of Serious Adverse Events |
Screening, Baseline, Month 4, Month 8, Month 12
|
|
Quality of life: EQ5D-5L questionnaires
Tidsramme: Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Quality of life will be assessed with the EQ5D-5L questionnaire |
Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
|
Work productivity and activity impairement questionnaires
Tidsramme: Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires |
Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Tarmsykdommer
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Gastroenteritt
- Inflammatoriske tarmsykdommer
- Crohns sykdom
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Pteriner
- Pteridiner
- Aminopterin
- Metotreksat
- CT-P13
- 2-mercaptopurine
Andre studie-ID-numre
- GT-2021-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .